



PATENT  
Docket No. 511582001620

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on October 3, 2002.

*Tami M. Procopio*  
Tami M. Procopio

RECEIVED  
OCT 10 2002  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Daniel E. H. AFAR, *et al.*

Serial No.: 09/455,486

Filing Date: 6 December 1999

For: NOVEL SERPENTINE  
TRANSMEMBRANE ANTIGENS  
EXPRESSED IN HUMAN CANCERS  
AND USES THEREOF

Examiner: G. B. Nickol, Ph. D.

Group Art Unit: 1642

**EXPEDITED PROCEDURE --**  
**EXAMINING GROUP 1642**

#  
257D  
KD  
10-29-02

**AMENDMENT TO SUPPLEMENT THE  
AMENDMENT UNDER 37 C.F.R. § 1.116  
FILED 3 JUNE 2002 AND NOT ENTERED**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This amendment supplements and corrects an obvious error in the amendment submitted 3 June 2002. The accompanying Request for Continued Examination has requested entry of the previously filed amendment, and thus the present supplementary amendment assumes that this has been entered.

In the amendment previously submitted, applicants erroneously neglected to delete the phrase "which cancer expresses a STEAP-2 protein" from the claims. The claims as now presented merely require an immunological response, including the production of antibodies. It

was understood from the discussion at the interview held on 18 March 2002, that this type of amendment would provide a satisfactory resolution to the outstanding rejection.

Enclosed is the following Exhibit A: Marked-up Version of Amendments to the Claims.